CCI: Polymer-free dual DES shows promise in first-in-human trial

07/30/2013 | Healio

In a feasibility trial of a polymer-free dual drug-eluting stent, Beijing researchers found no deaths, MI or stent thrombosis four months post-procedure and only three target lesion failure events linked to repeat revascularization at 18 months. In the study, reported in Catheterization and Cardiovascular Interventions, researchers placed the Bicare stent, a polymer-free nanotechnology stent that releases sirolimus and probucol, in 32 patients with a single de novo native coronary stenosis.

View Full Article in:

Healio

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC